US EditionStocks Making the Biggest Moves Premarket: Novo Nordisk, Tesla, Alphabet, Oscar Health & More
Novo Nordisk shares dropped 10% after a failed Alzheimer’s trial while Tesla and Alphabet gained on AI advancements and health insurers rose on ACA subsidy extension news.
8 Articles
8 Articles
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says - WSVN 7News | Miami News, Weather, Sports
(CNN) — An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk said Monday. In two Phase 3 trials of more than 3,800 adults receiving standard care for Alzheimer’s, the company evaluated whether an older pill form of semaglutide worked better than a placebo. The drug was shown to be safe and led to improvements in…
The vice president of a pharmaceutical company described Alzheimer's research as a lottery ticket: there could be new potential or nothing at all.
The title of the Danish drug manufacturer was on Monday the red lantern of the index STOXX 600. It is the lowest level since July 2021 for the action which has lost more than half of its value since the...
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
